The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Open accessAbstract
The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy (Podlaha et al., 2012; Landau et al., 2013) or treated with specific inhibitors (Ding et al., 2012) to those observed here.”
From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Ding et al., 2012
In the citing paper
“For example, the clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy 9.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationTumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citationWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citationCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489
Cited by
Sorted by citations
Items 201–300 of 999
Boyd, A. L., Aslostovar, L., Reid, J. C., Ye, W., Tanasijevic, B., Porras, D. P., Shapovalova, Z., Almakadi, M., Foley, R., Leber, B. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.007 · Cited by 197
Tumor evolution and chemoresistance in ovarian cancer
Kim, S., Han, Y., Kim, S. I., Kim, H., Kim, S. J., & Song, Y. S. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0063-0 · Cited by 188
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Smith, C. C., Paguirigan, A. L., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T. C., Chin, C.-S., Asthana, S., Olshen, A. B., Travers, K. J., et al. (2017) · Blood · doi:10.1182/blood-2016-04-711820 · Cited by 185
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Bell, C. C., Fennell, K. A., Chan, Y.-C., Rambow, F., Yeung, M. M., Vassiliadis, D., Gonzalez, L. E. L., Yeh, P. S.-H., Martelotto, L. G., Rogiers, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10652-9 · Cited by 186
Expanding the computational toolbox for mining cancer genomes
Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 188
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 185
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
Grove, C. S., & Vassiliou, G. S. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.015974 · Cited by 202
Minimal residual disease in acute myeloid leukaemia
Hourigan, C. S., & Karp, J. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.100 · Cited by 182
Savage, K. I., Gorski, J. J., Barros, E. M., Irwin, G. W., Manti, L., Powell, A. J., Pellagatti, A., Lukashchuk, N., McCance, D. J., McCluggage, W. G., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.021 · Cited by 177
Luthra, R., Patel, K. P., Reddy, N. G., Haghshenas, V., Routbort, M. J., Harmon, M. A., Barkoh, B. A., Kanagal‐Shamanna, R., Ravandi, F., Cortes, J. E., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.093765 · Cited by 184
ClonEvol: clonal ordering and visualization in cancer sequencing
Dang, H. X., White, B. S., Foltz, S. M., Miller, C. A., Luo, J. R., Fields, R. C., & Maher, C. A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx517 · Cited by 180
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Morita, K., Kantarjian, H. M., Wang, F., Yan, Y., Bueso-Ramos, C., Sasaki, K., Issa, G. C., Wang, S., Jorgensen, J. L., Song, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6757 · Cited by 181
Vinci, M., Burford, A., Molinari, V., Kessler, K., Popov, S., Clarke, M., Taylor, K. R., Pemberton, H. N., Lord, C. J., Gutteridge, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0086-7 · Cited by 192
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
Huls, G. A., Chitu, D. A., Havelange, V., Jongen‐Lavrencic, M., van de Loosdrecht, A. A., Biemond, B. J., Sinnige, H. A. M., Hodossy, B., Graux, C., Kooy, R. V. M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879866 · Cited by 178
Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin
Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J., Skambraks, S., et al. (2021) · Blood · doi:10.1182/blood.2020007626 · Cited by 183
Acute myeloid leukemia—Major progress over four decades and glimpses into the future
Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24246 · Cited by 174
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J. M., Rijal, S., MacRaild, S., Zhang, L., Teh, T., Tiong, I. S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0261-3 · Cited by 171
Ehmsen, S., Pedersen, M. H., Wang, G., Terp, M. G., Arslanagic, A., Hood, B. L., Conrads, T. P., Leth‐Larsen, R., & Ditzel, H. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.104 · Cited by 174
Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia
Fayyad‐Kazan, H., Bitar, N., Najar, M., Lewalle, P., Fayyad‐Kazan, M., Badran, R., Hamade, E., Daher, A., Hussein, N., ElDirani, R., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-31 · Cited by 178
Kuipers, J., Jahn, K., Raphael, B. J., & Beerenwinkel, N. (2017) · Genome Research · doi:10.1101/gr.220707.117 · Cited by 168
Genetics of progression from MDS to secondary leukemia
Menssen, A. J., & Walter, M. J. (2020) · Blood · doi:10.1182/blood.2019000942 · Cited by 182
Defining principles of combination drug mechanisms of action
Pritchard, J. R., Bruno, P. M., Gilbert, L. A., Capron, K. L., Lauffenburger, D. A., & Hemann, M. T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210419110 · Cited by 164
Phylogenetic Quantification of Intra-tumour Heterogeneity
Schwarz, R. F., Trinh, A. C., Sipos, B., Brenton, J. D., Goldman, N., & Markowetz, F. M. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003535 · Cited by 168
Visualizing tumor evolution with the fishplot package for R
Miller, C. A., McMichael, J. F., Dang, H. X., Maher, C. A., Ding, L., Ley, T. J., Mardis, E. R., & Wilson, R. K. (2016) · BMC Genomics · doi:10.1186/s12864-016-3195-z · Cited by 173
Clonal evolution in hematological malignancies and therapeutic implications
Landau, D. A., Carter, S. L., Getz, G. A., & Wu, C. J. (2013) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 173
Mullenders, J., Aranda-Orgillés, B., Lhoumaud, P., Keller, M., Pae, J., Wang, K., Kayembe, C., Rocha, P. P., Raviram, R., Gong, Y., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151323 · Cited by 172
Measuring cancer evolution from the genome
Graham, T. A., & Sottoriva, A. (2016) · The Journal of Pathology · doi:10.1002/path.4821 · Cited by 182
Stone, R. M., Manley, P. W., Larson, R. A., & Capdeville, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017011080 · Cited by 170
Evolutionary medicine: its scope, interest and potential
Stearns, S. C. (2012) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2012.1326 · Cited by 163
DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias
Yang, L., Rodriguez, B. A. T., Mayle, A., Park, H. J., Lin, X., Luo, M., Jeong, M., Curry, C. V., Kim, S.-B., Ruau, D., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.003 · Cited by 165
Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer
Wang, X., Ricciuti, B., Nguyen, T. T., Li, X., Rabin, M. S., Awad, M. M., Lin, X., Johnson, B. E., & Christiani, D. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3991 · Cited by 163
Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia
Paguirigan, A. L., Smith, J. L., Meshinchi, S., Carroll, M. P., Maley, C. C., & Radich, J. P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0763 · Cited by 159
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 164
Ljungström, V., Cortese, D., Young, E., Pandzic, T., Mansouri, L., Plevová, K., Ntoufa, S., Baliakas, P., Clifford, R. M., Sutton, L., et al. (2015) · Blood · doi:10.1182/blood-2015-10-674572 · Cited by 158
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Testa, U., Pelosi, E., & Castelli, G. (2019) · Cancers · doi:10.3390/cancers11091358 · Cited by 160
Heralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach‐Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 156
SiFit: inferring tumor trees from single-cell sequencing data under finite-sites models
Zafar, H., Tzen, A., Navin, N. E., Chen, K., & Nakhleh, L. K. (2017) · Genome biology · doi:10.1186/s13059-017-1311-2 · Cited by 156
Advances in understanding tumour evolution through single-cell sequencing
Kuipers, J., Jahn, K., & Beerenwinkel, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.001 · Cited by 148
Myeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, J., Gelsi‐Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 163
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
Oakes, C. C., Claus, R., Gu, L., Assenov, Y., Hüllein, J., Zucknick, M., Bieg, M., Brocks, D., Bogatyrova, O., Schmidt, C. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0349 · Cited by 153
Chicard, M., Daage, L. C., Clément, N., Danzon, A., Bohec, M., Bernard, V., Baulande, S., Bellini, A., Deveau, P., Pierron, G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1586 · Cited by 150
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 151
Fang, B., Kovačević, Ž., Park, K. C., Kalinowski, D. S., Jansson, P. J., Lane, D. J. R., Sahni, S., & Richardson, D. R. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.11.002 · Cited by 151
Allen, C. G., Hills, R. K., Lamb, K., Evans, C. J., Tinsley, S., Sellar, R. S., O'Brien, M. A., Yin, J., Burnett, A. K., Linch, D. C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.186 · Cited by 145
SF3B1 mutations in chronic lymphocytic leukemia
Wan, Y., & Wu, C. J. (2013) · Blood · doi:10.1182/blood-2013-02-427641 · Cited by 155
Single-cell paired-end genome sequencing reveals structural variation per cell cycle
Voet, T., Kumar, P., Loo, P. V., Cooke, S. L., Marshall, J., Lin, M., Esteki, M. Z., der Aa, N. V., Mateiu, L. M., McBride, D. J., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt345 · Cited by 149
How I treat relapsed or refractory AML
DeWolf, S., & Tallman, M. S. (2020) · Blood · doi:10.1182/blood.2019001982 · Cited by 145
Recent advances in acute myeloid leukemia stem cell biology
Horton, S. J., & Huntly, B. J. P. (2012) · Haematologica · doi:10.3324/haematol.2011.054734 · Cited by 149
Schmidt, M., Rinke, J., Schäfer, V., Schnittger, S., Kohlmann, A., Obstfelder, E., Kunert, C., Ziermann, J., Winkelmann, N., Eigendorff, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.272 · Cited by 142
Mitochondrial levels determine variability in cell death by modulating apoptotic gene expression
Márquez-Jurado, S., Díaz‐Colunga, J., das Neves, R. P., Martinez-Lorente, A., Almazán, F., Guantes, R., & Iborra, F. J. (2018) · Nature Communications · doi:10.1038/s41467-017-02787-4 · Cited by 134
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
Zhao, B., Sedlak, J. C., Srinivas, R. R., Creixell, P., Pritchard, J. R., Tidor, B., Lauffenburger, D. A., & Hemann, M. T. (2016) · Cell · doi:10.1016/j.cell.2016.01.045 · Cited by 139
Singh, A. K., Arya, R. K., Maheshwari, S., Singh, A., Meena, S., Pandey, P., Dormond, O., & Datta, D. B. (2014) · International Journal of Cancer · doi:10.1002/ijc.28804 · Cited by 145
Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 138
Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort
Michor, F., & Beal, K. P. (2015) · Cell · doi:10.1016/j.cell.2015.11.002 · Cited by 143
Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells
Perry, J. M., Fang, T., Roy, A., Lin, T. L., He, X., Chen, S., Lü, X., Nemechek, J. M., Ruan, L., Yu, X., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0507-y · Cited by 140
Holstege, H., Pfeiffer, W., Sie, D., Hulsman, M., Nicholas, T. J., Lee, C. C., Ross, T., Lin, J., Miller, M. A., Ylstra, B., et al. (2014) · Genome Research · doi:10.1101/gr.162131.113 · Cited by 152
Navigating cancer network attractors for tumor-specific therapy
Creixell, P., Schoof, E. M., Erler, J. T., & Linding, R. (2012) · Nature Biotechnology · doi:10.1038/nbt.2345 · Cited by 136
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
Madan, V., Shyamsunder, P., Han, L., Mayakonda, A., Nagata, Y., Sundaresan, J., Kanojia, D., Yoshida, K., Ganesan, S., Hattori, N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.69 · Cited by 137
Nguyen, A., Yoshida, M., Goodarzi, H., & Tavazoie, S. F. (2016) · Nature Communications · doi:10.1038/ncomms11246 · Cited by 136
Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance
van Gastel, N., Spinelli, J. B., Sharda, A., Schajnovitz, A., Baryawno, N., Rhee, C., Oki, T., Grace, E., Soled, H. J., Milosevic, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.009 · Cited by 148
Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
Hirsch, P., Zhang, Y., Tang, R., Joulin, V., Boutroux, H., Pronier, E., Moatti, H., Flandrin‐Gresta, P., Marzac, C., Bories, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12475 · Cited by 144
Chao, M. P., Gentles, A. J., Chatterjee, S., Lan, F., Reinisch, A., Corces, M. R., Xavy, S., Shen, J., Haag, D., Chanda, S., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.018 · Cited by 141
Mayakonda, A., & Koeffler, H. P. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/052662 · Cited by 136
Zeijlemaker, W., Kelder, A., Oussoren-Brockhoff, Y. J. M., Scholten, W. J., Snel, A. N., Veldhuizen, D., Cloos, J. J., Ossenkoppele, G. J., & Schuurhuis, G. J. (2015) · Leukemia · doi:10.1038/leu.2015.252 · Cited by 134
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme
Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1151 · Cited by 131
Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing
Hughes, A. E. O., Magrini, V. J., Demeter, R., Miller, C. A., Fulton, R. S., Fulton, L., Eades, W. C., Elliott, K., Heath, S. E., Westervelt, P., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004462 · Cited by 131
The interplay of leukemia cells and the bone marrow microenvironment
Duarte, D., Hawkins, E. D., & Celso, C. L. (2018) · Blood · doi:10.1182/blood-2017-12-784132 · Cited by 135
Molecular Pathology of Breast Cancer
Allison, K. H. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpiv9iq1mrqmoo · Cited by 131
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
McNeer, N. A., Philip, J., Geiger, H. M., Ries, R. E., Lavallée, V., Walsh, M. F., Shah, M. J., Arora, K. S., Emde, A., Robine, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0402-3 · Cited by 130
Cohesin mutations in human cancer
Hill, V. K., Kim, J.-S., & Waldman, T. A. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.05.002 · Cited by 137
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples
Martelotto, L. G., Baslan, T., Kendall, J., Geyer, F. C., Burke, K. A., Spraggon, L., Piscuoglio, S., Chadalavada, K., Nanjangud, G. J., Ng, C. K. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4279 · Cited by 126
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Casuscelli, J., Weinhold, N., Gundem, G., Wang, L., Zabor, E. C., Drill, E. N., Wang, P. I., Nanjangud, G. J., Redzematovic, A., Nargund, A. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92688 · Cited by 131
Stem cells in cancer initiation and progression
Bajaj, J., Diaz, E., & Reya, T. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201911053 · Cited by 132
Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J., Miotke, L. K., Hopmans, E. S., Xu, H., Pai, R. K., Palm, C., Regan, J. F., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0428-9 · Cited by 126
Leukemic stem cells: identification and clinical application
Hanekamp, D., Cloos, J. J., & Schuurhuis, G. J. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2221-5 · Cited by 134
Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 137
Gutmann, D. H., McLellan, M. D., Hussain, I., Wallis, J. W., Fulton, L., Fulton, R. S., Magrini, V. J., Demeter, R., Wylie, T., Kandoth, C., et al. (2012) · Genome Research · doi:10.1101/gr.142604.112 · Cited by 130
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Ramos, N. R., Mo, C. C., Karp, J. E., & Hourigan, C. S. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040665 · Cited by 127
Mossner, M., Jann, J.-C., Wittig, J., Nolte, F., Fey, S., Nowak, V., Obländer, J., Pressler, J., Palme, I., Xanthopoulos, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679167 · Cited by 135
Ferrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 132
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Antoun, N. B., & Chioni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512222 · Cited by 141
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
TrAp: a tree approach for fingerprinting subclonal tumor composition
Strino, F., Parisi, F., Micsinai, M., & Kluger, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt641 · Cited by 126
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 139
Origins of aberrant DNA methylation in acute myeloid leukemia
Schoofs, T., Berdel, W. E., & Müller‐Tidow, C. (2013) · Leukemia · doi:10.1038/leu.2013.242 · Cited by 127
Gay, L. J., Baker, A., & Graham, T. A. (2016) · F1000Research · doi:10.12688/f1000research.7210.1 · Cited by 129
Hackl, H., Astanina, K., & Wieser, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0416-0 · Cited by 130
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Cocciardi, S., Dolnik, A., Kapp‐Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnoeder, T. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09745-2 · Cited by 128
Next generation sequencing in cancer research and clinical application
Shyr, D., & Liu, Q. (2013) · Biological Procedures Online · doi:10.1186/1480-9222-15-4 · Cited by 130
Molecular therapy for acute myeloid leukaemia
Coombs, C. C., Tallman, M. S., & Levine, R. L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.210 · Cited by 125
Multiple myeloma clonal evolution in homogeneously treated patients
Corre, J., Cleynen, A., Robiou-du-Pont, S., Buisson, L., Bolli, N., Attal, M., Munshi, N. C., & Avet‐Loiseau, H. (2018) · Leukemia · doi:10.1038/s41375-018-0153-6 · Cited by 128
Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Vosberg, S., & Greif, P. A. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22806 · Cited by 135
Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy
Ho, T., Kim, H. S., Chen, Y., Li, Y., LaMere, M. W., Chen, C., Wang, H., Gong, J., Palumbo, C. D., Ashton, J. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3217 · Cited by 128
Lorz, A., Lorenzi, T., Clairambault, J., Escargueil, A. E., & Benoît Perthame, B. (2014) · Bulletin of Mathematical Biology · doi:10.1007/s11538-014-0046-4 · Cited by 137
Targeting cell cycle regulators in hematologic malignancies
Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 128
Minor clone provides a reservoir for relapse in multiple myeloma
Magrangeas, F., Avet‐Loiseau, H., Gouraud, W., Lodé, L., Decaux, O., Godmer, P., Garderet, L., Voillat, L., Facon, T. T. F., Stoppa, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.226 · Cited by 122
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Short, N. J., Kantarjian, H. M., Ravandi, F., & Daver, N. G. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719827310 · Cited by 122
Computational analysis of cancer genome sequencing data
Cortés‐Ciriano, I., Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., & Park, P. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00431-y · Cited by 118
Metadata
- Authors
- Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Ley, Timothy J.
- ORCID
- Ding, Li
- Ley, Timothy J.
- Larson, David E.
- Miller, Christopher A.
- Koboldt, Daniel C.
- Welch, John S.
- Ritchey, Julie K.
- McLellan, Michael D.
- McMichael, Joshua F.
- Lu, Charles
- Shen, Dong
- Fulton, Robert S.
- Fulton, Lucinda L.
- Chen, Ken
- Magrini, Vincent J.
- McGrath, Sean D.
- Vickery, Tammi L.
- Wendl, Michael C.
- Heath, Sharon
- Watson, Mark A.
- Link, Daniel C.
- Tomasson, Michael H.
- Payton, Jacqueline E.
- Kulkarni, Shashikant
- Walter, Matthew J.
- Graubert, Timothy A.
- Mardis, Elaine R.
- Wilson, Richard K.
- DiPersio, John F.
- Venue
- Nature
- Published
- 2012-01
- Volume
- 481
- Issue
- 7382
- Pages
- 506-510
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3267864
- OpenAlex
- W2093144236
- Cited by
- 1,993
- References
- 30
- Citations by year
- 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
- FWCI
- 149.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Foundation for Barnes-Jewish Hospital (00335-0505-02)
- National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
- National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
- MeSH terms
- Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
